Tozorakimab: a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

Autor:	I C Scott, E England, D G Rees, T Erngren, C Chaillan Huntington, K F Houslay, D A Sims, C Hollins, E C Hinchy, C Colley, D J Corkill, E S Cohen
Rok vydání:	2022
Zdroj:	05.01 - Airway pharmacology and treatment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8e5ec96827e28a40808419e77b522376 https://doi.org/10.1183/13993003.congress-2022.2467 Zobrazit plný text záznamu